KerlingAKckMTegtburUGramsLWeber-SpickschenSHankeAet al
Figure 2: Categorical weight loss of either 5%, 10%, or 15% in the randomly assigned treatment groups administered either 0.3 mg of cagrilintide, 0.6 mg of cagrilintide, 1.2 mg of cagrilintide, 2.5 mg of cagrilintide, 4.5 mg of cagrilintide, 3.0 mg of liraglutide, or a placebo
The FDA is not legally bound by advisory committee recommendations and has previously diverged from PCAC consensus, though doing so is uncommon
Our providers screen for contraindications and health conditions, dose appropriately based on your goals and response, monitor for side effects or complications, and adjust protocols based on your progress and feedback
The FDA declared the semaglutide shortage resolved in February 2025, which technically limits when 503A pharmacies can compound semaglutide
Repatha is generally not recommended for use during pregnancy as its effects on an unborn baby are unknown